Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Requirement Related to IRBs May Delay Clinical Trials: Medical Associations
June 5, 2006
- CMIC Allies with KineMed to Add Value to Aborted Compounds
June 5, 2006
- R&D NEWS IN BRIEF
June 5, 2006
- Sales Force Effectiveness Japan
June 5, 2006
- Combined Sales, Profits of Top 10 Companies Up in FY2005
May 29, 2006
- Toyama Chemical: Pharma Div. Sales Down 8.4%
May 29, 2006
- Metabolic Syndrome Estimated to Affect 9.4 Mil. Japanese Over 40
May 29, 2006
- Astellas: Stronger Sales, Profits Driven by Overseas Growth
May 29, 2006
- Seikagaku Corp.: Good US Sales Prop Up Business
May 29, 2006
- Eisai: Another Year of Record Sales and Profits
May 29, 2006
- Kirin: Pharma Division Posts 14.5% Growth in Sales
May 29, 2006
- Taisho: Pharma Sales Up 0.6%, Self-medication Sales Down 4.7%
May 29, 2006
- JT: New 3-Year Management Plan Aimed at Long-term Growth
May 29, 2006
- Shionogi: Royalties Prop Up Profits Despite Lower Sales
May 29, 2006
- Industry Should Oppose Unreasonable Proposals: New FPMAJ President
May 29, 2006
- Mr T. Korekane Appointed President: Ono
May 29, 2006
- So-net M3 Starts Trial Run of "Doctors Blog"
May 29, 2006
- Santen: Ethical Drug Sales Up Domestically and Overseas
May 29, 2006
- STATISTICS
May 29, 2006
- Meiji Seika: Sales of Ethical Drugs Up 6.2% to \94,353 Mil.
May 29, 2006
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…